Vancomycin-Associated Nephrotoxicity

Occurrence and Economic Impact of Nephrotoxicity Associated With Vancomycin Exposure

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01216540

Enrollment

398

Registered

2010-10-07

Start date

2010-11-30

Completion date

2011-04-30

Last updated

2022-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotoxicity

Keywords

vancomycin, nephrotoxicity, length of stay, costs

Brief summary

The primary goal of this study is to determine if there is an association between greater exposure to vancomycin and the development of nephrotoxicity. The secondary goal is to estimate the costs to the hospital associated with these nephrotoxic events.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 years or older at time of hospital admission * Had an absolute neutrophil count of ≥ 1000 cells/mm\^3 * Received \> 48 hours of intravenous vancomycin therapy * Had one or more vancomycin trough levels reported within the 96 hours after therapy initiation * Had a baseline serum creatinine level of \< 2.0 mg/dL and baseline creatinine clearance level of ≥ 30 mL/min

Exclusion criteria

* Previous diagnosis of cystic fibrosis

Design outcomes

Primary

Measure	Time frame
Time to nephrotoxicity	within 72 hours post completion of vancomycin therapy

Secondary

Measure	Time frame
Hospital costs	until discharge
Length of stay	until discharge

Countries

United States

Outcome results